Identification and efficacy assessment of novel immunoprotective antigens from Mycoplasma synoviae for vaccine development Authors: Luru Zhao, Weiqi Guo, Bin Zhang, Xiaochuan Tang, Yinan Liu, Jingyi Liang, Qi Wu, Yanqing Bao, Mingxing Tian, Shaohui Wang, Jingjing Qi Published: 2025 ABSTRACT AbstractMycoplasma synoviae (MS) is a significant pathogen mentioned by the World Organisation for Animal Health (WOAH) and has caused substantial economic losses to the global poultry industry. The prevention and control strategies are primarily based on flock purification, antibiotic treatment, and vaccination. Given the high cost and extended timeline of flock purification, along with the growing antibiotic resistance, vaccination remains the most effective strategy for preventing MS transmission. This study employed pangenome analysis combined with reverse vaccinology (RV) to identify protective antigens against MS. At last, three proteins namely VY320 (elongation factor P), VY430 (50S ribosomal protein L6), and VY930 (YbhB/YbcL family Raf kinase inhibitor-like protein), were selected to assess their potential as candidate subunit vaccines. Furthermore, a lesion scoring method using a foot pad challenge model was established to evaluate the protective efficacy of the MS vaccine. The results indicated that the VY930 protein is an effective antigen and can activate strong humoral and cellular immunity responses in immunized flocks, superior to the inactivated vaccine. The screening strategy, evaluation methods, and related findings of this study may provide valuable insights into the prevention and control of MS.Subject terms: Diseases, Immunology, Microbiology Introduction Since 1954, avian mycoplasmosis has been recognized as a significant disease affecting poultry flocks1. Among them, Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) are mentioned as important pathogens for poultry by the World Organization of Animal Health (WOAH). As a result of effective control strategies for MG, MS has emerged as an important cause of economic loss in the poultry industry2. MS is a major avian pathogen that commonly causes airsacculitis, synovitis, respiratory diseases, as well as reduced egg production and hatchability in chickens and turkeys3,4. MS spreads horizontally and vertically5, resulting significant economic losses to the poultry industry6. The prevention and control strategies of avian mycoplasmosis are primarily based on flock purification, antibiotic treatment, and vaccination7. Flock purification requires substantial human and economic resources. Antibiotic treatment provides a rapid and effective approach for the clinical management of Mycoplasma infections. However, the widespread application of antibiotics has exacerbated antibiotic resistance in MS strains7,8. Therefore, vaccination remains the most effective long-term strategy for prevention, control, and decontamination. MS vaccines are generally categorized into three types: inactivated vaccines, live attenuated vaccines, and genetically engineered subunit vaccines. Currently, the temperature-sensitive attenuated MS-H strain (Vaxsafe®MS, Australia) is widely used in many countries9. However, this vaccine is only suitable for uninfected MS flocks10 and can be horizontal transmission after immunization9. Thus, its widespread use may impact the decontamination strategy. Moreover, the use of live vaccines may interfere with serological diagnostics, leading to false-positive outcomes. The YBF-MS1 (Qingdao Yebio, China) strain is the only inactivated vaccine officially registered for use in China. Inactivated vaccines share the high production costs associated with the MS-H strain and induce significant serological responses, which can interfere with monitoring programs10. Subunit vaccines based on certain proteins are considered effective for the defense and control of MS, and conserved antigens are theoretically useful for various infections11. Recent studies have investigated subunit vaccines against various pathogens, which have demonstrated enhanced protective efficacy. Li12 evaluated the protective efficiency of a recombinant subunit vaccine against porcine deltacoronavirus (PDCoV) and found that the S-protein-based subunit vaccine provided greater protection against PDCoV infection than the inactivated vaccine. Zhang13 evaluated the relative survival rates of prepared inactivated vaccine and OmpA subunit vaccine after Aeromonas hydrophila infection, demonstrating that the subunit vaccine showed superior immune protection compared to the inactivated vaccine. To some extent, the effectiveness of this vaccine depends on the screening of antigenic proteins. Additionally, it is essential to anticipate the immunogenic and other relevant properties of the candidate proteins14. Hence, with the advancement of bioinformatics technology, the development of subunit vaccines based on pangenome analysis and reverse vaccinology (RV) approaches has become a viable alternative. In this study, the complete genomes of 23 MS strains were analyzed, and 102 core genes were identified by pangenome analysis. Subsequently, protective antigens were screened from the core genome using RV. These candidate antigens were evaluated through animal experiments. The results showed that the VY930 antigen exhibited a strong protective effect against MS infection. This study lays the foundation for the development of MS vaccine and provides an innovative strategy for the prevention, control, and purification of MS. Methods Animals and ethics statements The specific pathogen-free (SPF) chickens (male, four weeks old for the challenge experiments and one day old for the protective efficacy evaluation) were purchased from Zhejiang Lihua Agricultural Technology Company. New Zealand white rabbits (female, two months old) were purchased from Shanghai Jiaotong University Agricultural Experiment and Practice Field Co. All animal experiments were performed at Chinese Academy of Agricultural Sciences (CAAS). All animals were housed in animal facilities with free access to water and food and were monitored at least twice daily. All procedures were conducted in accordance with the guidelines of Shanghai Laboratory Animal Welfare and Ethics, and in compliance with international regulations. The approval number for the ethical review of experimental animal welfare is SV-20240705-Y01 and SV-20231215-Y06. To reduce animal suffering, the chickens were first anesthetized by intramuscular injection of Zoletil 50 (Virbac, French) at a dosage of 10 mg/kg, euthanasia was then performed via rapid cardiac puncture with blood aspiration. After confirming euthanasia, the chickens were subjected to necropsy to assess pathological lesions. Bacterial strains and vector The standard MS strain WVU1853 were purchased from the China Veterinary Culture Collection Center (CVCC, China). The MS YC1 was isolated from the swollen foot pads of diseased chickens in Jiangsu province, China15. Escherichia coli (E. coli) strains DH5α and BL21 (DE3) were purchased from Tiangen Biotech (Beijing, China) Co., Ltd. The pCold Ⅰ expression vector was stored in our laboratory. Genome retrieval and pangenome analysis A total of 23 complete genomes of MS strains (GCA_000969765.1, GCA_000385095.1, GCA_900475235.1, GCA_002009055.1, GCA_013393745.1, GCA_003147565.1, GCA_003586085.1, GCA_026427675.1, GCA_020150295.1, GCA_020276585.1, GCA_000008245.1, GCA_022354765.1, GCA_020276565.1, GCA_026427695.1, GCA_020276605.1, GCA_009671165.1, GCA_020276625.1, GCA_020276645.1, GCA_019334145.1, GCA_014805575.1, GCA_026016825.1, GCA_026016845.1, GCA_026016765.1) were retrieved from the NCBI database. The CDS of all genomes were annotated using Prokka (version 1.14.6)16. All annotated sequences were analyzed using Roary (version 3.13.0)17 to extract the core proteomes. All settings were configured to default values. Reverse vaccinology analysis for protein prioritization After the core proteome was screened by pangenome analysis, antigenicity was predicted using the VaxiJen 2.0 server18 (https://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html), and sequences with high antigenicity scores were selected. Next, high antigenicity protein sequences were analyzed to determine subcellular localization using the PSORTb server19 (http://www.psort.org/psortb/). Subsequently, protein transmembrane regions were predicted using the TMHMM server20 (https://services.healthtech.dtu.dk/services/TMHMM-2.0), and non-transmembrane proteins were selected for further validation. In addition, the signal peptides of the proteins were predicted using the SignalP 6.0 server21 (https://services.healthtech.dtu.dk/services/SignalP-6.0). The screened protein sequences were evaluated for allergenicity using the AllerTOP server22 (https://www.ddg-pharmfac.net/allertop_test). Finally, the screened protein sequences were analyzed for virulence factors using the VFDB database (https://www.mgc.ac.cn/VFs) to identify potential virulence-related proteins. Subsequently, the candidate proteins were subjected to secondary and tertiary structure predictions. The secondary structures of the proteins were predicted using PSIPRED server (http://bioinf.cs.ucl.ac.uk/psipred). The tertiary structure of the proteins was predicted using SWISS-MODEL (https://swissmodel.expasy.org). Immune simulation analysis To evaluate the immune response elicited by the vaccine, an immune simulation was performed using the C-ImmSim server23 to generate the immune response profile of the designed vaccine. C-ImmSim is an agent-based immune response simulator that uses the Celada-Seiden model to simulate the immune response. All settings were retained at default values, except for the adjustment of the “Simulation Steps” to 105. The age of immunization was selected as 7 and 21 days of age. Overlap PCR amplification and construction of the recombinant plasmids The features of VY320, VY430 and VY930 are presented in Table 1. When analyzing the gene sequence and constructing vectors, mutations from TGA to TGG were required to better suit the E. coli expression system. Primers were designed using MS WVU1853 genomic DNA as a template (Table 2). Table 1Features of the selected genesNo.Gene namesGene AnnotationAmino (aa)Molecular Mass (kDa)TGA codons1VY320Elongation factor P18621.012VY43050S ribosomal protein L618019.303VY930Hypothetical protein22124.93 Features of the selected genes Table 2Primers used for Overlap PCR amplification of the selected genesGene namesPrimer namesSequences (5’-3’)Amplicon size (bp)Restriction EndonucleaseVY320320-1 Fcgcggatccatgattgaagttaacaaatt312BamHI320-1 RgaaattcatctcCcattctacttttg320-2 FcaaaagtagaatgGgagatgaatttc272320-2 RccggaattctttgctttttccgacEcoRIVY430430-Fcgcggatccatgtcacgtgttgg540BamHI430-RccggaattctttagaagctgttttcccttcEcoRIVY930930-1 Fccgctcgagatgcataaattaggtaataaaac144XhoI930-1 RtggcattttgtcCcattttaattc930-2 FgaattaaaatgGgacaaaatgcca112930-2 RcattaactgcaacCcagtgaat930-3 FattcactgGgttgcagttaatg130930-3 RagttatatccttgCcataataagttgc930-4 FgcaacttattatgGcaaggatataact350930-4 RcgcggatccgttagatccagBamHI Primers used for Overlap PCR amplification of the selected genes The fragments should be amplified for fusion before obtaining the full-length candidate gene. Using the VY320 gene as an example, primers 320-1 F/1 R and 320-2 F/2 R were used for the first round of PCR amplification, respectively. Following PCR amplification, the resulting fragments were purified and subsequently used as templates for overlap-extension PCR amplification. In the second round of amplification, the full-length of VY320 gene sequence was amplified using primers 320-1 F/2 R. The PCR conditions were as follows: 35 cycles of denaturation at 98 °C for 10 s, annealing at 55 °C for 15 s and extension at 72 °C for 5 s. The amplification products were incorporated into the expression vector pCold I, and then introduced into E. coli BL21 (DE3) competent cells (Tiangen). Expression and purification of the candidate antigens E.coli BL21 (DE3) cells (Tiangen) containing the recombinant plasmids were cultured in LB medium with ampicillin (100 μg/ mL) until the OD 600nm reached 0.6. The cells were then induced with 0.05 mg/mL IPTG and cultured for 24 h at 16 °C. After induction, the bacteria cells were disrupted using a high-pressure cell crusher (Ningbo Scientz Biotechnology, China). The resulting samples were centrifuged at 8000 × g for 20 min at 4°C. The supernatant was collected and purified using ProteinIso® Ni-NTA Resin (TransGen Biotech, China) according to the manufacturer’s instructions. The candidate protein was washed and eluted using a linear imidazole gradient ranging from 10−500 mM. The concentrations of proteins were determined using a BCA Protein Assay kit (Beyotime, China). Establishment of the challenge model Molecular biology tests and Mycoplasma isolation were performed on diseased chickens from various provinces and farms, and MS YC115 was selected as the experiment strain. To evaluate the inoculation dose and route, the broth culture of MS YC1 was diluted to concentrations of 104, 105, and 106 CCU/mL in PBS. For each concentration, two distinct challenge methods, namely foot pad inoculation24 and wing vein inoculation25, were evaluated separately. The four-week-old SPF chickens were randomly divided into eight groups after being raised to five weeks of age, with eight chickens in each group. In the challenge group, each chicken was inoculated with 0.1 mL of MS bacteria, while the control group received the same volume of PBS. Clinical symptoms were recorded weekly. At three weeks post challenge, all groups were dissected after euthanasia, and lesions in the air sac and other tissues were recorded. Vaccine preparation and immunogenicity assessment To prepare the vaccine candidates, the purified protein was diluted to 1 mg/mL with PBS and emulsified by mixing with an equal volume of the Freund’s adjuvant. Two-month-old New Zealand white rabbits were immunized via multipoint subcutaneous injection. For the primary immunization, the protein was emulsified with complete Freund’s adjuvant (500 μg per rabbit), followed by booster immunizations with incomplete Freund’s adjuvant (300 μg per rabbit) at two-week intervals. Each experimental group consisted of one rabbit. Serum samples were collected one week after the second and third immunizations and stored at -20 °C until analysis. Protein immunogenicity was evaluated by Western blot25 using the rabbit antisera as primary antibodies and a goat anti-rabbit IgG-HRP antibody (Abcam, UK) as the secondary antibody. Establishment of lesion scoring method and initial screening of protective antigens The subunit vaccine was prepared by emulsifying the purified protein with an equal volume of the Freund’s adjuvant, following the same procedure as previously described. Twenty-five one-day-old SPF chickens were raised in the animal house and adapted to the environment until they were one week old. They were then randomly allocated into five groups, including three experimental groups immunized with subunit vaccines (Group A: VY320; Group B: VY430; Group C: VY930), an adjuvant-immunized control group (Group D), and a PBS-challenge control group (Group E). The prepared subunit vaccines were administered at dose of 150 μg/chicken26 (primary immunization at one week of age) and 100 μg/chicken27 (booster immunization at two weeks post primary immunization)24,28–32 following the procedure shown in Fig. 1. The vaccines were administered to chickens via multi-point subcutaneous injection in the neck region. Two weeks after the booster immunization24,28, chickens were challenged with the MS YC1 strain via foot pad injection. Clinical symptoms were observed and scored at 7, 14, and 21 days post-challenge to evaluate the protective efficacy of the candidate subunit vaccines against MS infection. Schematic diagram of immunization and challenge experiment. The subunit vaccine was prepared by emulsifying the purified protein with an equal volume of the Freund’s adjuvant. The prepared subunit vaccines were administered at dose of 150 μg/chicken (primary immunization at one week of age) and 100 μg/chicken (booster immunization at two weeks post primary immunization). Two weeks after the booster immunization, chickens were challenged with the MS YC1 strain via foot pad injection. Clinical symptoms were observed and scored at 7, 14, and 21 days post-challenge to evaluate the protective efficacy of the candidate subunit vaccines against MS infection. ELISA detection of the antigen-specific serum antibodies in vaccinated chickens Serum samples were collected weekly after immunization via wing vein puncture from vaccine-immunized groups and the adjuvant-immunized control group. Antigen-specific antibody titers were quantified by ELISA using the respective proteins. Briefly, 96-well plates were coated with antigen (5 µg/mL) overnight at 4 °C. After washing with PBST (0.05% Tween-20 in PBS), plates were blocked with 5% skimmed milk for 2 h at 37 °C. The collected serum samples (1:100 dilution in PBST) were incubated for 2 h at 37°C, followed by incubation with a goat anti-chicken IgY-HRP antibody (1:10,000; Abcam). The plates were then washed three times with PBST, and color development used TMB Substrates (Tiangen) for 15 min before termination with 50 μL of 2 M H2SO4. Absorbance was measured at OD 450 nm. A sample is considered positive when the ratio of the test value from vaccine-immunized group to that of the adjuvant-immunized control group is ≥ 2.125. The highest dilution that ratio ≥ 2.1 is defined as the antibody titer of the test serum. Evaluation of the protective efficacy of the VY930 vaccine The VY930 subunit vaccine and the MS inactivated vaccine were selected for further protective efficacy evaluation. After raising 60 one-day-old SPF chickens to the age of one week, they were randomly assigned into four groups: two vaccine immunization groups (Group A: VY930 subunit vaccine; Group B: MS inactivated vaccine), an adjuvant-immunized control group (Group C), and a PBS challenge control group (Group D). Immunization and observation procedures followed the scheme in Fig. 1. Protection efficacy was evaluated using the established lesion scoring method. Splenic lymphocyte isolation Two weeks after the booster immunization, three chickens were randomly selected from each three groups: two vaccine immunization groups (Group A: VY930 subunit vaccine; Group B: MS inactivated vaccine), an adjuvant-immunized control group (Group C). The chickens were first anesthetized by intramuscular injection of Zoletil 50 (Virbac) at a dosage of 10 mg/kg, euthanasia was then performed via rapid cardiac puncture with blood aspiration. The sera were separated and stored at -20 °C. After confirming euthanasia, the chickens underwent spleen removal. Primary splenic lymphocytes were isolated from chickens using a commercial Chicken Splenic Lymphocyte Isolation Kit (Solarbio, China). Briefly, spleens were aseptically dissected and mechanically dissociated by gently grinding with a syringe plunger (10 mL) through a cell strainer. The resulting single-cell suspension was filtered and rinsed with tissue diluent. Lymphocytes were then purified by density-gradient centrifugation (800 × g, 25 min) after layering the suspension over the isolation solution. The lymphocyte layer was carefully aspirated, washed twice with cell washing solution, and resuspended in RPMI-1640 medium (Thermo Fisher Scientific, USA) for subsequent analysis. T-cell subtype analysis by flow cytometry The proportions of CD4+ and CD8+ T lymphocytes were assessed with an ACEA Novocyte 3130 flow cytometer. Briefly, the isolated lymphocytes were diluted to 1 × 10⁶ cells/mL and incubated with fluorochrome-conjugated antibodies: PE-CD3 (0.3 μg), FITC-CD4 (1 μg), and APC-CD8 (0.1 μg). Antibody incubation was performed at 25°C for 30 min in the dark. After incubation, the cells were washed twice with PBS by centrifugation (300 × g, 5 min) and resuspended in 300 µL PBS for flow cytometric analysis. Statistical analysis Statistical analyses were performed using one-way ANOVA in GraphPad Prism 10 to assess significant differences in lesion scores and T-cell subtype distributions. Differences were considered significant if p < 0.05. All data visualizations were conducted using GraphPad Prism 10. Results Pangenome analysis of MS complete genomes The complete genomes of 23 MS strains were annotated using Prokka v1.14.6. Genome annotation files were converted to GFF3 format and subsequently analyzed using Roary v3.13.0 for pangenome characterization. Phylogenetic reconstruction was performed based on core genome alignment (Fig. 2a). The pangenome analysis identified 345 genes, comprising 102 core genes (present in ≥ 90% of strains) and 243 accessory genes (Fig. 2b). Pangenome composition and phylogenetic analysis of MS strains. a Phylogenetic tree consisting of the whole genome of 23 MS strains; b Results of pangenome analysis of the whole genome sequences of 23 MS strains. Selection and characterization of candidate vaccine antigens The core proteomes identified through pangenome analysis were subjected to further analysis. The antigenicity and subcellular localization prediction indicated that 12 proteins exhibited high antigenicity (score ≥ 0.7), including 10 cytoplasmic proteins and 2 proteins with unknown localization. Subsequently, five proteins with molecular mass greater than 10 kDa, lacking transmembrane domains and signal peptides, were selected for further analysis. The sequence information for these five candidate proteins is presented in Table 3. The five candidate protein were analyzed for allergenicity, and the results demonstrated that they are predicted to be probable non-allergens. Further predictions for virulence genes revealed that none were detected in any of these protein sequences. Based on protein size, three candidate proteins with greater molecular mass (VY320, VY430, and VY930) were selected for subsequent analyses in this study. Table 3Candidate proteinsNo.Protein namesAntigenicity predictionSubcellular localizationMolecular Mass (kDa)1group_3290.9183Cytoplasmic13.82VY3200.8776Cytoplasmic21.03group_3090.8595Cytoplasmic13.74VY4300.8332Cytoplasmic19.45VY9300.7412Unknown24.9 Candidate proteins Structural prediction and analysis Secondary structures of VY320, VY430, and VY930 were predicted using the PSIPRED server. And the results revealed the VY320 protein comprising 6.45% α-helices, 46.24% β-sheets, and the remaining regions exhibited random coils (Fig. 3a). The VY430 protein comprising 19.44% α-helices, 37.22% β-sheets, and the remaining regions exhibited random coils (Fig. 3b). The VY930 protein comprising 12.67% α-helices, 22.17% β-sheets, and the remaining regions exhibited random coils (Fig. 3c). All three proteins predominantly characterized by β-sheets and random coils, a structural feature known to enhance antigen recognition by leukocytes and antibodies27. The tertiary structures of candidate proteins were predicted using SWISS-MODEL through homology modeling. The prediction results revealed that the VY320 protein shared 70.27% sequence identity with PDB template A5IY97.1.A, the VY430 protein showed 99.44% sequence identity with Q4A5D6.1.A, and the VY930 protein demonstrated 99.55% sequence identity with Q4A5M4.1.A. Secondary and tertiary structure prediction and quality assessment of the proteins. a The secondary structure of the vaccine sequence predicted by PSIPRED server. The 3D structure of the vaccine predicted using the SWISS-MODEL. The ramachandran plot generated for the VY320 protein structure. b The secondary structure of the vaccine sequence predicted by PSIPRED server. The 3D structure of the vaccine predicted using the SWISS-MODEL. The ramachandran plot generated for the VY320 protein structure. c The secondary structure of the vaccine sequence predicted by PSIPRED server. The 3D structure of the vaccine predicted using the SWISS-MODEL. The ramachandran plot generated for the VY320 protein structure. In addition, the structural stability of the proteins was evaluated using Ramachandran plots. The results indicated that the structures of the three proteins were relatively stable. Additionally, the MolProbity and Clash scores for the VY320 structure were 1.12 and 0.68, respectively. The Ramachandran plot showed that 93.99% of residues were in the favored region, 0.55% were outliers, and 0.00% were rotamer outliers. The MolProbity and Clash scores for the VY430 structure were 0.83 and 0.00, respectively. The Ramachandran plot showed that 98.31% of residues were in the favored region, 0.00% were outliers, and 2.68% were rotamer outliers. The MolProbity and Clash scores for the VY930 structure were 1.05 and 0.00, respectively. The Ramachandran plot showed that 94.06% of residues were in the favored region, 0.00% were outliers, and 1.58% were rotamer outliers. Computational immune response evaluation Immunogenicity of the candidate vaccine was assessed using C-ImmSim server for in silico immune simulations. The simulation analysis of the candidate antigens revealed the antibody titer and the cytokine trends in Fig. 4. The results demonstrated a significant increase in antibody titers and cytokine levels following the second immunization, including IFN-γ and IL-2. In conclusion, the candidate subunit vaccine effectively stimulates high levels of antibodies and activated cytokines, demonstrating strong immunogenicity and potential efficacy against the pathogen. Immune simulation. Using the C-ImmSim server to generate the immune response profile of the designed vaccine. All settings were retained at their default values, except for the adjustment of the “Simulation Steps” parameter to 105. The immunization ages were set at 7 and 21 days. a The antibody concentrations and cytokines of VY320 protein. b The antibody concentrations and cytokines of VY430 protein. c The antibody concentrations and cytokines of VY930 protein. Cloning, expression and purification of the candidate proteins Following PCR amplification, the fragments and full-length of the VY320, VY430, and VY930 genes were successfully amplified from the Overlap PCR amplification (Fig. 5a, b). The codon-optimized sequences were successfully cloned into the pCold Ⅰ vector and transformed into E. coli BL21 (DE3) cells (Tiangen) (Fig. 5c). Recombinant proteins expression were induced with 0.05 mg/mL IPTG, and the target proteins were predominantly soluble, exhibiting significant accumulation in the supernatant (Fig. 5d–f). Following successful purification, the proteins were concentrated using ultrafiltration tubes (Sigma-Aldrich, USA). The final concentration of the purified proteins was adjusted to 1 mg/mL. Vector construction and immunogenicity evaluation of proteins. a Amplification of gene fragments from VY320, VY430 and VY930. b Full-length amplification of genes from VY320, VY430 and VY930. c Recombinant plasmid identification. d Protein induced expression of E. coli BL21 (pCold I-VY320). e Protein induced expression of E. coli BL21 (pCold I-VY430). f Protein induced expression of E. coli BL21 (pCold I-VY930). M: Protein Marker; Lane 1: Whole cell proteins of recombinant strains before induction; Lane 2: Whole cell proteins of recombinant strains after induction; Lane 3: Supernatant proteins of recombinant strains after induction; Lane 4: Precipitated proteins of recombinant strains after induction. g Protein immunogenicity identification of VY320 protein. h Protein immunogenicity identification of VY430 protein. i Protein immunogenicity identification of VY930 protein. M: Protein Marker; Lane 1: Western Blot reaction of proteins with antisera. Immunogenicity assessment of the candidate antigens For Western blot analysis, immune sera from immunized rabbits were used as the primary antibody. Specific bands of the expected molecular mass were detected (Fig. 5g–i), confirming that each candidate protein was specifically recognized by its respective antiserum. These results demonstrated that the recombinant proteins exhibit strong immunoreactivity, supporting their potential immunogenicity. Determination of MS challenge route and dose Through pathogenicity assessment of the challenge strain in chickens, it was found that the three tested concentrations did not induce obvious clinical symptoms following wing vein inoculation. Only mild signs of airsacculitis were observed at the concentrations of 2 × 104 CCU/chicken and 2 × 105 CCU/chicken following wing vein inoculation. While foot pad inoculation with MS YC1 (2 × 103, 2 × 104 or 2 × 105 CCU/chicken) induced pronounced clinical signs. Of these, results showed that at a challenge dose of 2 × 10³ CCU/chicken, the incidence rate was only 37.5%, and all infection groups exhibited only mild foot pad swelling, while most chickens displayed no clinical or pathological signs. At a challenge dose of 2 × 10⁴ CCU/chicken, the infection rate increased to 87.5%, exceeding 80%, and the flock developed typical foot pad swelling and joint inflammation. Thus, this concentration was identified as the minimum challenge dose for MS YC1. When the challenge dose was increased to 2×10⁵ CCU/chicken, the incidence rate reached 100% (including 100% foot pad swollen, 37.5% joint swollen, and 12.5% airsacculitis (Table 4), with more severe foot pad and joint swelling compared with the 10⁴ CCU/chicken group. Further revealed the presence of caseous exudate adhering to the air sacs in some chickens, representing a characteristic manifestation of MS-induced airsacculitis during respiratory infection. To better simulate clinically relevant infection conditions, the 2×10⁵ CCU/chicken concentration will be used as the challenge dose for subsequent vaccine efficacy evaluations. Table 4Pathogenicity of MS YC1 strainsGroupChallenge routeChallenge doseSwollen joints(%)Swollen foot pads (%)Airsacculitis(%)AWing vein2×1030 (0/8)0 (0/8)0 (0/8)2×1040 (0/8)0 (0/8)12.5 (1/8)2×1050 (0/8)0 (0/8)12.5 (1/8)PBS0 (0/8)0 (0/8)0 (0/8)BFood pad2×1030 (0/8)37.5 (3/8)0 (0/8)2×10437.5 (3/8)87.5 (7/8)0 (0/8)2×10537.5 (3/8)100 (8/8)12.5 (1/8)PBS0 (0/8)0 (0/8)0 (0/8) Pathogenicity of MS YC1 strains Establishment of lesion scoring method We ultimately chose foot pad challenge to simulate clinical infection and evaluate vaccine protection efficacy. Chickens were scored and evaluated at 7, 14 and 21 days post challenge, and disease severity was categorized into six grades (grade 0, 1, 2, 3, 4, and 5), corresponding to scores of 0, 0.2, 0.4, 0.8, and 1.0. Grade 0 indicates no clinical signs of disease, grades 1 ~ 3 represent localized disease within the foot pad, and grades 4 ~ 5 indicate more severe disease extending beyond the foot pad. The specific scoring criteria are shown in Fig. 6 and are described as follows. Chickens classified as Grade 0 show no clinical signs. Grade 1 chickens exhibit mild swelling of the foot pad on the challenged side, which must be carefully compared with the unchallenged side. Furthermore, no other clinical signs are observed in Grade 1. Grade 2 displays more pronounced swelling of the foot pad on the challenged side, without progression to severe swelling of the entire foot and without additional symptoms. In Grade 3, the swelling of the foot pad on the challenged side is severe and extends to the entire foot, significantly impairing normal walking and resulting in lameness. However, no swelling occurs on the unchallenged side, and the metatarsal and tarsal joints remain unaffected. Grade 4 presents the similar symptoms to Grade 3, with additional swelling spreading to the foot pads. Furthermore, the metatarsal and tarsal joints on the challenged side show slight swelling, and airsacculitis may be observed upon necropsy. Grade 5 chickens exhibit severe swelling of the foot pads and pronounced swelling of the metatarsal and tarsal joints, along with signs of airsacculitis upon necropsy. Score assessment of different grades of foot pad lesion. a Defined criteria for immunoprotection scoring levels and corresponding point allocation. Chickens were scored and evaluated at 7, 14 and 21 days post challenge, and disease severity was categorized into six grades (grade 0, 1, 2, 3, 4, and 5), corresponding to scores of 0, 0.2, 0.4, 0.8, and 1.0. Grade 0 show no clinical signs. Grade 1 chickens exhibit mild swelling of the foot pad on the challenged side, which must be carefully compared with the unchallenged side, and have no other clinical signs. Grade 2 displays more pronounced swelling of the foot pad on the challenged side, without progression to severe swelling of the entire foot and without additional symptoms. In Grade 3, the swelling of the foot pad on the challenged side is severe and extends to the entire foot, significantly impairing normal walking and resulting in lameness. No swelling occurs on the unchallenged side, and the metatarsal and tarsal joints remain unaffected. Grade 4 presents the similar symptoms to Grade 3, with additional swelling spreading to the foot pads. Furthermore, the metatarsal and tarsal joints on the challenged side show slight swelling, and airsacculitis may be observed upon necropsy. Grade 5 chickens exhibit severe swelling of the foot pads and pronounced swelling of the metatarsal and tarsal joints, along with signs of airsacculitis upon necropsy. b The specific correspondence between lesion severity and scoring criteria is illustrated. Evaluation of the protective efficacy of the candidate proteins The protective efficacy of the VY320, VY430, and VY930 vaccines was evaluated, and the clinical lesion scores of chickens after MS YC1 challenge are shown in Fig. 7. It was found that the adjuvant-immunized control group developed disease in all flocks by the first week post-challenge. During the second and third weeks post-challenge, the adjuvant-immunized control group demonstrated a progressive worsening of clinical symptoms. Airsacculitis was observed, and the challenge strain was successfully detected and isolated only in the adjuvant-immunized group. In contrast, the overall lesion scores in the subunit vaccine-immunized groups were consistently lower compared to those in the adjuvant-immunized control group (Fig. 7e). All subunit vaccine immunized groups exhibited significant protective efficacy against MS YC1 challenge, with the VY930 subunit vaccine-immunized group exhibiting the lowest lesion scores. By the final week of observation, the total lesion score was 1.8 in the VY320 group, 1.2 in the VY430 group, and only 0.4 in the VY930 group. In addition, significance analysis in the Fig. 7c showed that the protective efficacy of the VY930 subunit vaccine-immunized group were significant (p < 0.01) higher than that of the adjuvant-immunized control group, whereas the other two subunit vaccine-immunized groups indicated no obvious difference (p > 0.05) by the second week post-challenge. The PBS-challenge control group did not develop any clinical symptoms during the observation period. Evaluation and scoring of the protective efficiency of three candidate subunit vaccine. a Clinical scoring results. Note1: Number of positive samples/all samples2; Mean ± standard deviation. b Clinical symptom scores recorded one week after challenge with the MS YC1 strain. c Clinical symptom scores recorded two weeks after challenge with the MS YC1 strain. d Clinical symptom scores recorded three weeks after challenge with the MS YC1 strain. e Dynamic assessment in total clinical lesion scores within each group following MS YC1 challenge. Note: ***p < 0.001; **p < 0.01; ns represents p > 0.05. Reevaluation of the protective efficacy of the VY930 vaccine The experimental data comparing the immune protective efficacy of VY930 subunit vaccine with that of inactivated vaccine are shown in Fig. 8. The clinical lesion scores of chickens immunized with the VY930 subunit vaccine and the inactivated vaccine were significantly lower than those of the adjuvant-immunized group. In the first week after challenge with MS YC1, the adjuvant-immunized control group exhibited disease in all chickens, with an average lesion score of 0.33 per chicken and a total group score of 5. In the VY930 subunit vaccine-immunized group and the inactivated vaccine-immunized group, only a few chickens exhibited mild foot pad swelling in the first week post-challenge, with average lesion scores of 0.07 and 0.08, and group scores of 1.0 and 1.2, respectively. In the second week post-challenge with MS YC1, clinical symptoms in the adjuvant-immunized control group significantly worsened, including swelling of the foot pad and joints. However, the vaccine-immunized groups did not exhibit any symptoms in joints. Furthermore, a dynamic analysis of the protective efficacy in immunized chickens revealed that the protective efficacy of the VY930 subunit vaccine was significantly higher than that of the adjuvant-immunized control group and slightly better than that of the inactivated vaccine in the second week after MS YC1 challenge (Fig. 8c). And the average lesion scores were 0.31 and 0.37, respectively, indicating the superior protective efficacy of VY930. By the third week, airsacculitis was only found in the adjuvant-immunized control group (Fig. 8a). The PBS control group exhibited no clinical symptoms throughout the entire observation period. Overall, the VY930 subunit vaccine group demonstrated slightly lower clinical scores than the inactivated vaccine group, indicating superior protective efficacy. Evaluation and scoring of the protective efficiency of VY930 subunit and inactivated vaccine. a Clinical scoring results. Note1: Number of positive samples/all samples2; Mean ± standard deviation. b Clinical symptom scores recorded one week after challenge with the MS YC1 strain. c Clinical symptom scores recorded two weeks after challenge with the MS YC1 strain. d Clinical symptom scores recorded three weeks after challenge with the MS YC1 strain. e Dynamic assessment in total clinical lesion scores within each group following MS YC1 challenge. Note: ***p < 0.001; **p < 0.01; ns represents p > 0.05. Dynamics of specific serum antibodies To evaluate humoral immunity, sera were collected from seven days post immunization to assess antibody titers suing ELISA. The results indicated that the antibody titers induced by the candidate proteins exhibited a significant upward trend with increasing immunization duration. Antibody titers peaked 14 days following the booster vaccination. The antibody titers for VY320, VY430, and VY930 were 1:51,200, 1:102,400, and 1:102,400, respectively (Fig. 9). Antibodies levels in sera of chickens after the inoculation of the subunit vaccines at different days detected by ELISA. The antibody titers induced by the candidate proteins exhibited a significant upward trend with increasing immunization duration. Antibody titers peaked 14 days following the booster vaccination. The antibody titers for VY320, VY430, and VY930 were 1:51,200, 1:102,400, and 1:102,400, respectively. T-cell subtype analysis To evaluate the cellular immune response, splenic lymphocytes were analyzed by flow cytometry to quantify CD3+, CD4+, and CD8+ T cell populations (Fig. 10). The results showed that CD3+ T cell levels increased in vaccine-immunized groups. In the VY930 subunit-immunized group, both CD3+CD4+ (p < 0.05) and CD3+CD8+ (p < 0.01) T cell populations showed a significant increase. In the inactivated vaccine-immunized group, CD3+CD4+ T cells exhibited a slight increase (p = ns), while CD3+CD8+ T cells showed a slight decrease (p = ns). Subsequently, the ratio of CD4+ and CD8+ was analyzed to assess relative changes in helper and cytotoxic T cell populations. The ratio slightly decreased in the VY930 subunit vaccine-immunized group (p = ns), while it slightly increased in the inactivated vaccine-immunized group (p = ns). T-lymphocyte subpopulation sorting. Note: ***p < 0.001; **p < 0.01; *p < 0.05; ns represents p > 0.05. The CD3+ T cell levels increased in vaccine-immunized groups. In the VY930 subunit vaccine-immunized group, both CD3+CD4+ (p < 0.05) and CD3+CD8+ (p < 0.01) T cell populations showed a significant increase. In the inactivated vaccine-immunized group, CD3+CD4+ T cells exhibited a slight increase (p = ns), while CD3+CD8+ T cells showed a slight decrease (p = ns). The ratio slightly decreased in the VY930 subunit vaccine-immunized group (p = ns), while it slightly increased in the inactivated vaccine-immunized group (p = ns). Discussion MS is a respiratory pathogen that listed by the World Organisation for Animal Health (WOAH)7, known to cause infectious synovitis and respiratory tract infections in poultry33. The disease spreads rapidly through both horizontal and vertical transmission, and persists as a chronic infection, making it extremely difficult to eradicate. Currently, the primary strategies for preventing and controlling the disease include flock purification, antibiotic therapy and vaccination. Among these, vaccination remains the most effective strategy for preventing MS transmission24. Although MS vaccines do not provide complete sterilizing immunity, studies have demonstrated their ability to mitigate disease severity and reduce infection rates34,35. Therefore, the development of safe and effective MS vaccines is essential for effective infection control and the successful implementation of flock purification strategies33. Pangenome analysis enables the identification of core genomic elements and conserved protein sequences within bacterial populations, offering a powerful approach for antigen discovery36. The screened core proteome may serve as the potential vaccine targets37, particularly for subunit vaccine development. This method effectively accelerates antigen screening and provides new strategies for vaccine development. Recently, these technologies have been widely applied in designing vaccines against a variety of pathogens. Guo38 developed a multi-epitope vaccine targeting Mycobacterium avium subspecies paratuberculosis (MAP) using pangenomes and RV approaches, providing a theoretical foundation for the development of an effective MAP vaccine. Similarly, Dar39 used this approach to identify protective antigens against Mycobacteroides abscessus, and sequence-based analysis confirmed its immunological potential. In this study, core antigens selected through pangenome analysis exhibited high conservation across MS strains, suggesting their ability to induce cross-protective immunity against diverse MS isolates. Further screening was conducted using reverse vaccinology approaches to identify proteins with good cross-protection. Sun et al.24 used Biopython software to analyze the core genes with high copy numbers in virulent strains HB03 were identified as potential antigen candidates. And nine candidate genes were ultimately selected for vaccine development, including Vlha-related regions, the molecular chaperone DnaK, and elongation factors. Among these, elongation factors were also examined in this study (VY320 is elongation factor P), but the protective effect was not satisfactory. In addition, compared with the approach combining immunoproteomics and RV analysis reported by Zhang et al.25, the method used in this study substantially enhances experimental efficiency. By integrating pangenome and RV analyses, this study adopted a more comprehensive strategy to identify conserved, immunogenic with broad protective potential. The bioinformatics-based screening results were further validated through animal experiments to evaluate the immunoprotective efficacy of the selected subunit vaccine candidates. Through bioinformatics screening and data analysis, the cytoplasmic proteins VY320 and VY430, as well as the unknown protein VY930, were identified. Annotation analysis of the protein sequence of VY320 revealed that it corresponds elongation factor P (EF-P), which is present in all bacteria40. EF-P promotes peptide bond formation by stabilize the tRNA at the P site41, thereby enhancing protein translation. Additionally, Khazani found that EF-P is a potential drug target against Bordetella pertussis42. VY430 is the 50S ribosomal protein L6, which has been identified through immune-informatics as a potential target for the development of an endocarditis vaccine43. VY930 is a YbhB/YbcL family Raf kinase inhibitor-like protein that may be involved in regulating protein phosphorylation by kinases44. Currently, these three proteins have not been experimentally verified for immune protection in MS. Based on the above results, these three proteins were selected as targets for immunogenicity and protective efficacy verification. Vaccination can induce protective immunity against pathogens by targeting immunogenic antigens45. While proteins with higher predicted antigenicity scores are theoretically excepted to exhibit stronger immunogenicity, and adjuvants formulations can enhance vaccine efficacy46, clinical evaluations revealed unexpected findings. The VY930, despite having the lowest in silico antigenicity score, provided superior protective efficacy, compared to higher-scoring candidates (VY320 and VY430). Similar to Sun’s findings24, the protective efficacy of the conserved target proteins identified through bioinformatics screening was verified to be below 80%, showing slight discrepancies from the predicted results. These results highlight that while bioinformatics tools aid antigen screening, experimental validation remains critical for vaccine development. It is widely known that the production of specific antibodies is demonstrated to be a key indicator for assessing vaccine immunogenicity. However, Yi30 demonstrated that the antibody levels induced after vaccination do not play a significant role in protective efficacy, emphasizing the importance of cellular immunity against MS infection. Researches have indicated that even in the absence of pathogen-specific antibodies, cellular immune responses may be essential for effective protection, underscoring the role of CD8+ T lymphocytes47,48. This study compared the protective efficacy of the VY930 subunit vaccine with that of the inactivated vaccine and found that the VY930 subunit vaccine-immunized group significantly increased both CD3+CD4+ (p < 0.05) and CD3+CD8+ (p < 0.01) T cell populations, while the inactivated vaccine-immunized group only exhibited a slight increase in CD3+CD4+ T cells (p = ns). These results demonstrated that VY930 exhibited superior protective efficacy. Therefore, the limited clinical protective efficacy of inactivated vaccines may be related to the unsuccessfully activate CD8+ T lymphocytes. In addition, studies have found that subunit vaccines are associated with a reduced CD4/CD8+ T ratio. High degree of immunosenescence may lead to lower vaccine responses, and the lower CD4/CD8+ T ratio in the subunit vaccine group in this study may be related to this phenomenon49. In this study, Freund’s adjuvant was employed to formulate a water-in-oil emulsion with the antigen. This delivery system enables sustained antigen release, thereby eliciting robust and durable antibody responses. Although water-in-oil adjuvants offer superior antigen persistence and safety profiles compared to conventional oil-based formulations, they may induce localized adverse effects including granuloma formation and inflammatory reactions at the injection site50. Beyond the widely used Freund’s adjuvant, various adjuvant classes can be utilized to enhance immune responses, including aluminum salts (alum), microbial-derived adjuvants (Mycobacterium, Bacillus subtilis, Bordetella pertussis, and bacterial lipopolysaccharides), liposomal formulations, inorganic adjuvants, and novel adjuvants systems. To maximize the immunoprotective efficacy of the VY930 subunit vaccine, adjuvants commonly employed in avian vaccines, such as Montanide ISA adjuvant51 and β-defensin52, along with optimization of the emulsification ratio, should be considered. Among these, Montanide adjuvants have been demonstrated to be suitable for immunotherapy owing to their metabolizable safety profile and are widely employed in the formulation of veterinary emulsion vaccines53. This study demonstrated that the VY930 subunit vaccine achieved optimal protective efficacy with Freund’s adjuvant, suggesting that further improvement may be attainable through the use of Montanide adjuvant. Our future work will therefore incorporate Montanide adjuvant into the vaccine formulation to enhance its protective performance. Furthermore, the combined application of vaccines is expected to enhance host immune protection. As demonstrated by Yi et al.30, a vaccination strategy integrating both inactivated and subunit vaccines against MS induced significantly stronger protective immune responses than single-vaccine administration. These results are consistent with similar findings reported for other avian pathogens, such as duck Riemerella anatipestifer54, underscoring the value of combined immunization strategies in achieving superior protection. The VY930 subunit vaccine identified in this study may therefore be a suitable candidate for use in combination with inactivated vaccines, and further experimental validation is warranted to assess its potential for synergistic protective. In addition to combined immunization strategies, our laboratory is also initiating research on multi-epitope subunit vaccines. In a study by Zhang et al.27, a multi-epitope subunit vaccine was constructed by conjugating epitopes from immunoprotective antigens. Vaccinated chickens exhibited significantly reduced air sac lesion scores, decreased tracheal mucosal thickness, and lower MS loads in throat swabs compared to unvaccinated groups controls, indicating that multi-epitope subunit vaccines represent a promising approach for effective control of MS infection. There is currently no standardized method for evaluating Mycoplasma vaccines. Existing evaluation method includes air sac lesion scoring, tracheal mucosal thickness assessment, histopathological section assessment, and MS colonization measurement. These evaluation methods are relatively complex. This study established a scoring evaluation method based on foot pad challenge, which assess protective efficacy through observation of clinical symptoms and integrates data presentation to enhance clarity of the results. Considering that different MS isolates cause tissue-specific symptoms, we plan to develop strains with different tissue tropisms and conduct a comprehensive evaluation of the protective efficacy of this candidate vaccine. This study aimed to identify protective antigens against MS through pangenome analysis combined with RV approaches and to evaluate their potential as candidate vaccines. Based on the characteristics of the candidate proteins, we ultimately selected three proteins that have not been previously used for the evaluation of protective efficacy against MS, namely VY320 (elongation factor P), VY430 (50S ribosomal protein L6), and VY930 (YbhB/YbcL family Raf kinase inhibitor-like protein). Furthermore, we established a lesion scoring method using a foot pad challenge model to evaluate the protective efficacy of the candidate vaccine. The results indicated that the VY930 protein is an effective antigen and can activate strong humoral and cellular immunity responses in immunized flocks, superior to the inactivated vaccine. The screening strategy, evaluation methods, and related findings of this study provide valuable insights into the vaccine design and the prevention and control of MS. Supplementary information Supplementary figures Acknowledgements This study was supported by the National Key Research and Development Program of China (2023YFD1800602) and Technology Innovation Program of Chinese Academy of Agricultural Sciences (CAAS-ASTIP-2021-SHVRI). The author would like to thank Kaiqin Zhang and Zhiyang Wang for their assistance in animal blood collection and dissection, and teacher Zhixin Zhao for assistance with the flow cytometry assay in this study. Author contributions L.Z. performed the experiments, drafted and revised the manuscript. W.G. designed the experiment and analyzed relevant data. B.Z., Y.L., J.L., and Q.W. participated in animal experiments. X.T. provided detailed guidance on the experiment. Y. B. and M. T. helped to revise the manuscript. J.Q. and S.W. conceived the study, designed the experiment, revised and finalized the manuscript. All authors read and approved the final manuscript. Data availability All data supporting the findings of this study are available within the paper and its Supplementary Information. Furthermore, it is important to note that the three proteins screened in this study, VY320, VY430, and VY930, correspond to NCBI accession numbers WP_011283574.1, WP_011283764.1, and WP_011283676.1, respectively. Further inquiries can be directed to the corresponding authors. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Shaohui Wang, Email: shwang@shvri.ac.cn. Jingjing Qi, Email: qijingjing@shvri.ac.cn. Supplementary information The online version contains supplementary material available at 10.1038/s41541-025-01354-z. References Associated Data Supplementary Materials Supplementary figures Data Availability Statement All data supporting the findings of this study are available within the paper and its Supplementary Information. Furthermore, it is important to note that the three proteins screened in this study, VY320, VY430, and VY930, correspond to NCBI accession numbers WP_011283574.1, WP_011283764.1, and WP_011283676.1, respectively. Further inquiries can be directed to the corresponding authors.